On March 16, 2023 Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics to improve patient care, reported financial results for the fourth quarter ended December 31, 2022 and provided a corporate update (Press release, Immunome, MAR 16, 2023, View Source [SID1234628897]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Looking back on the past year, the transformative strategic collaboration with AbbVie highlighted the disruptive nature of our discovery platform in finding novel antibody-target pairs based on human memory B-cell response ," stated Purnanand Sarma, Ph.D., President and CEO of Immunome. "We look forward to continuing to execute on our momentum throughout the upcoming year as we advance our pipeline, including an IND submission for our lead oncology program, IMM-ONC-01 (anti-IL-38 antibody), and working closely with Abbvie on our collaboration to ultimately make a difference in cancer patients’ lives."

Highlights

AbbVie and Immunome Announced Strategic Collaboration to Discover Multiple Novel Oncology Targets. In January 2023, Immunome entered into a strategic collaboration and option agreement with AbbVie for the discovery of up to 10 novel antibody-target pairs arising from three specified tumor types derived from Immunome’s Discovery Engine. Key financial terms of the collaboration and option agreement include:

· $30 million upfront
· $70 million in platform milestones
· Low single digit millions options payments per target
· $120 million per target in development and first commercial sale milestone
· $150 million per target in sales based milestones
· Tiered royalties on global sales

· Preclinical Data on Novel Anti-EPN1 Antibody IMM20059 at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s 37th Annual Meeting. In November 2022, Immunome presented a poster presentation of IMM20059, Immunome’s novel anti-EPN1 antibody, at the SITC (Free SITC Whitepaper) Annual Meeting. IMM20059 in combination with anti-PD-L1 atezolizumab demonstrated significant tumor regression compared to IMM20059 or atezolizumab treatment alone, suggesting a potential combinatorial effect, or a greater than 50% reduction in tumor volume (p<0.05), between the two anti-tumoral pathways

Immunome published a paper highlighting the importance of tumor and lymph node-derived B cells for the discovery of antibodies directed at potentially novel targets.
· IMM-BCP-01 Update (COVID-19 Antibody Cocktail): Immunome has decided to seek a partner in order to continue the trial and for any further development activities. Immunome has successfully completed dosing of the first cohort of patients in a Phase 1b with no significant treatment-related adverse events

Financial Highlights

Cash and cash equivalents: As of December 31, 2022 cash and cash equivalents totaled $20.3 million.
· Research and development (R&D) expenses: R&D expenses for the three months ended December 31, 2022, were $4.3 million. R&D expenses for the year ended December 31, 2022 were $23.3 million.
· General and administrative (G&A) expenses: G&A expenses for the three months ended December 31, 2022, were $3.5 million. G&A expenses for the year ended December 31, 2022 were $13.6M.
· Net loss: Net loss attributable to common stockholders was $7.8 million, or $0.64 per share, for the three months ended December 31, 2022. Net loss attributable to common stockholders was $36.9 million, or $3.09 per share, for the year ended December 31, 2022.
· As of December 31, 2022, Immunome has 12,128,843 shares of common stock outstanding.